^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | trastuzumab-melanotransferrin conjugate (BT2111) (HER2-targeted antibody-drug conjugate, Melanotransferrin modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2653: Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: An in vivo study
Excerpt:
BT2111 reduced the number of preclinical human HER2+ breast cancer metastases in the brain of control animals (85 ± 6.3) by 68% (27.6 ± 3.9; P<0.001)...These results provide evidence that the MTf-trastuzumab conjugate, BT2111, has efficacy in treating brain metastasis in preclinical models and validates the role MTf has as a vector for the transport of antibodies across the BBB.
DOI:
10.1158/1538-7445.AM2014-2653
